Novavax (NVAX) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Novavax Reports Third Quarter 2018 Financial Results
November 7, 2018 4:05 PM ESTCompany to Host Conference Call Today at 4:30 p.m. ET
GAITHERSBURG, Md., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter and nine months ended September 30, 2018.
We remain on track to meet our 2018 objectives, as we continue to execute on our clinical milestones for ResVax and NanoFlu, said Stanley C. Erck, President and Chief Executive Officer of Novavax, Inc. In Prepare, our Phase 3 trial of ResVax, we will complete monitoring of the... More
